Want to see DNA full AI Analyst Report?
DNA Stock Chart & Stats
$8.86
-$0.35(-3.13%)
At close: 4:00 PM EST
$8.86
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.37 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.29M
Market Cap
$679.37M
Enterprise Value$825.36M
Total Cash (Recent Filing)$373.46M
Total Debt (Recent Filing)$410.70M
Price to Earnings (P/E)―
Beta2.91
Next Earnings
Aug 06, 2026EPS Estimate
-0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.37
Shares Outstanding53,361,140
10 Day Avg. Volume1,024,387
30 Day Avg. Volume1,288,409
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.91
Price to Sales (P/S)2.71
P/FCF Ratio-2.58
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue5.84
Enterprise Value/Gross Profit7.79
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$12.00Price Target Upside35.44% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-4.33
Revenue Forecast (FY)$123.10M
Bulls Say, Bears Say
Bulls Say
High Gross Margins (~81%)Sustained ~81% gross margins indicate the core biofoundry/platform has attractive unit economics: cost of goods is low relative to service pricing. That margin cushion supports long-term operating leverage as services, cloud lab and value-share deals scale, improving path to profitability if utilization rises.
Strong Cash Balance, No Bank DebtA $373M cash position with no bank debt provides meaningful runway to invest in Nebula, cloud lab and partnerships while executing cost reductions. This reduces near-term refinancing risk and gives management time to commercialize offerings before needing external capital, a durable strategic advantage.
Nebula Scale & Strategic PartnershipsRapid rack expansion and device integrations show operational progress toward an autonomous lab platform. Combined with sizable contracts and channel partners (cloud lab, AWS, Benchling, PNNL deal) this creates durable commercial optionality: repeatable services, platform lock-in and potential downstream value-share revenue if adoption continues.
Bears Say
Sharp Revenue DeclineA steep top-line contraction undermines scalability: declining revenue limits ability to absorb fixed operating costs and realize margin leverage from high gross margins. If revenue growth does not reaccelerate, cost cuts alone may be insufficient to reach sustainable profitability and the commercialization timeline extends.
Sustained Cash Burn And Negative FCFPersistent negative OCF and FCF signals ongoing reliance on external funding to sustain operations and invest in commercialization. Even with current cash, continued multiyear negative cash generation increases dilution or refinancing risk and constrains strategic flexibility to scale Nebula and channel investments if revenues lag.
Rising Leverage & Negative Returns On EquityIncreasing leverage and deeply negative ROE reflect worsening balance-sheet pressure from losses. Higher debt-to-equity reduces financial flexibility and magnifies risks if revenues falter, while negative returns indicate equity value is being eroded, limiting the company's ability to fund growth without dilutive or costly financing.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings, Inc.’s price range in the past 12 months?
Ginkgo Bioworks Holdings, Inc. lowest stock price was $5.37 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings, Inc.’s market cap?
Ginkgo Bioworks Holdings, Inc.’s market cap is $679.37M.
When is Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date?
Ginkgo Bioworks Holdings, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were Ginkgo Bioworks Holdings, Inc.’s earnings last quarter?
Ginkgo Bioworks Holdings, Inc. released its earnings results on May 07, 2026. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.211 by -$0.179.
Is Ginkgo Bioworks Holdings, Inc. overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings, Inc.’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
Ginkgo Bioworks Holdings, Inc. does not currently pay dividends.
What is Ginkgo Bioworks Holdings, Inc.’s EPS estimate?
Ginkgo Bioworks Holdings, Inc.’s EPS estimate is -0.91.
How many shares outstanding does Ginkgo Bioworks Holdings, Inc. have?
Ginkgo Bioworks Holdings, Inc. has 53,361,140 shares outstanding.
What happened to Ginkgo Bioworks Holdings, Inc.’s price movement after its last earnings report?
Ginkgo Bioworks Holdings, Inc. reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.211. Following the earnings report the stock price went down -13.469%.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings, Inc.?
Currently, no hedge funds are holding shares in DNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$12.00 (35.44% Upside)
$12.00 (35.44% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 201.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.85%
12-Months-Change
Fundamentals
Return on Equity
-57.31%
Trailing 12-Months
Asset Growth
-20.13%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc., alongside its subsidiary entities, provides an advanced technological platform focused on the engineering of cells. This proprietary system is utilized to manipulate cellular functions, facilitating the biological creation of various products. These outputs span from innovative pharmaceutical treatments and vital food components to sustainable chemicals designed to replace those traditionally sourced from petroleum. The enterprise caters to a broad spectrum of industries, encompassing specialized chemical manufacturing, the agricultural sector, food production, consumer goods, and pharmaceuticals. Furthermore, Ginkgo Bioworks has forged a partnership with Selecta Biosciences, Inc., for the joint advancement of the ImmTOR technology platform. The company, founded in 2008, is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced picture: meaningful operational and strategic progress in autonomous labs (Nebula), AI-driven experiments, partnerships and a strong cash position, alongside significant near-term financial challenges including a sharp revenue decline, ongoing losses, negative adjusted EBITDA and cash costs from excess leases and one-time payments. Execution and commercialization of Nebula, cloud lab and channel partnerships will determine whether the recent technical and commercial wins translate into durable revenue growth.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$12.00
▲(35.44% Upside)
Technical Analysis
Niagen Bioscience
―
Monopar Therapeutics Inc
―
Lyell Immunopharma
―
Jade Biosciences
―
AbSci
―
Ownership Overview
2.94% Insiders
15.87% Mutual Funds
25.72% Other Institutional Investors
40.17% Public Companies and Individual Investors